MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, RLYB had $9,925K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$9,925K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Accounts payable
    • Share-based compensation
    • Others
Negative Cash Flow Breakdown
    • Accrued expenses and operating l...
    • Deferred revenue
    • Prepaid expenses, operating leas...
    • Net accretion of discounts/premi...

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-8,278 -5,852 16,016 -19,142
Depreciation and amortization
3 3 35 54
Net accretion of discounts/premiums on debt securities
-51 -97 -113 -363
Share-based compensation
613 774 1,047 3,493
Gain on sale of joint venture
-0 22,350 -
Loss on investment in joint venture
0 0 0 -874
Prepaid expenses, operating lease right-of-use assets and other current assets
155 -815 773 2,085
Accounts payable
814 -143 150 -159
Accrued expenses and operating lease liabilities
-712 33 -350 -832
Deferred revenue
-212 -212 -212 -424
Net cash used in operating activities
-7,978 -4,679 -6,550 -18,584
Purchases of marketable securities
0 7,075 738 9,884
Proceeds from maturities of marketable securities
17,900 11,000 9,965 25,500
Proceeds from sale of common stock received from sale of joint venture
-0 20,000 -
Investment in joint venture
0 0 0 1,500
Net cash provided by investing activities
17,900 3,925 29,227 14,116
Proceeds from the issuance of common stock under the stock purchase plan
--0 10
Proceeds from the issuance of common stock from exercise of stock options
3 0 0 0
Proceeds from the issuance of common stock under the stock purchase plan
-16 --
Payments of offering costs
-0 0 0
Net cash provided by financing activities
3 6 0 10
Net increase in cash and cash equivalents
9,925 -748 22,677 -4,458
Cash and cash equivalents beginning of period
31,374 32,122 13,903 -
Cash and cash equivalents end of period
41,299 31,374 32,122 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof marketable...$17,900K Proceeds from theissuance of common stock...$3K Net cash provided byinvesting activities$17,900K Net cash provided byfinancing activities$3K Net increase in cashand cash...$9,925K Canceled cashflow$7,978K Accounts payable$814K Share-based compensation$613K Depreciation andamortization$3K Net cash used inoperating activities-$7,978K Canceled cashflow$1,430K Net loss-$8,278K Accrued expenses andoperating lease...-$712K Deferred revenue-$212K Prepaid expenses,operating lease...$155K Net accretion ofdiscounts/premiums on debt...-$51K

Rallybio Corp (RLYB)

Rallybio Corp (RLYB)